- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The Board of Starpharma Holdings Limited (Starpharma or Company) advises that the Company has today settled the placement of 11,853,844 fully paid ordinary shares in Starpharma at a share price of A$0.26 (Shares), to institutional, sophisticated and professional investors, as announced on 7 April 2009.
The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Corporations Act). Starpharma provides this notice in accordance with section 708A(5)(e) of the Corporations Act.
Starpharma notifies ASX (as operator of the prescribed financial market on which the ordinary shares are or are to be quoted) that, as at the date of this notice, Starpharma has complied with the provisions of Chapter 2M of the Corporations Act (as they apply to Starpharma), and with section 674 of the Corporations Act.
As at the date of this notice, Starpharma is not in possession of any excluded information within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.
About Starpharma Holdings Limited
Starpharma is a world leader in the development of nanotechnology-based pharmaceuticals and, through its US-based subsidiary Dendritic Nanotechnologies (DNT), a range of life-science and industrial uses.
Starpharma is listed on the Australian Securities Exchange (ASX: SPL)and its securities also trade in the US under the American Depository Receipts (ADR) program (OTCQX: SPHRY).
For more information, please click here
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Newly discovered 'design rule' brings nature-inspired nanostructures one step closer: Computer sims and microscopy research at Berkeley Lab yield first atomic-resolution structure of a peptoid nanosheet October 8th, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015